{
  "page_id": 1,
  "metadata": {
    "file_name": "doc_0816.png",
    "image_width": 754,
    "image_height": 1000
  },
  "lines": [
    {
      "text": "BLOOD LEVELS OF NEUROLEPTIC DRUGS IN",
      "bbox": [
        227,
        78,
        516,
        107
      ],
      "confidence": 0.989816427230835
    },
    {
      "text": "NON-RESPONDING CHRONIC SCHIZOPHRENIC PATIENTS",
      "bbox": [
        193,
        112,
        552,
        136
      ],
      "confidence": 0.9997456073760986
    },
    {
      "text": "Robert C. Smith, M.D., Ph.D.",
      "bbox": [
        255,
        259,
        477,
        280
      ],
      "confidence": 0.9589409828186035
    },
    {
      "text": "H. Dekirmenjian, Ph.D.",
      "bbox": [
        269,
        292,
        445,
        313
      ],
      "confidence": 0.9950802326202393
    },
    {
      "text": "John Crayton, M.D.",
      "bbox": [
        291,
        323,
        439,
        346
      ],
      "confidence": 0.9989007115364075
    },
    {
      "text": "David Klass, M.D.",
      "bbox": [
        299,
        357,
        437,
        376
      ],
      "confidence": 0.9966481328010559
    },
    {
      "text": "John M. Davis, M.D.",
      "bbox": [
        293,
        391,
        444,
        408
      ],
      "confidence": 0.9765337109565735
    },
    {
      "text": "From the Texas Research Institute of Mental Sciences, Houston, Texas (Dr. Smith),",
      "bbox": [
        64,
        502,
        701,
        525
      ],
      "confidence": 0.9936554431915283
    },
    {
      "text": "Manteno State Hospital, Manteno, I1linois (Drs. Smith, Crayton, and Klass), the",
      "bbox": [
        65,
        518,
        687,
        541
      ],
      "confidence": 0.9801822900772095
    },
    {
      "text": "Illinois State Psychiatric Institute, Chicago, Illinois (Dr. Dekirmenjian, Crayton,",
      "bbox": [
        66,
        536,
        718,
        557
      ],
      "confidence": 0.9820995330810547
    },
    {
      "text": "and Davis), and the Unviersity of Chicago, Department of Psychiatry (Drs. Crayton,",
      "bbox": [
        67,
        551,
        710,
        574
      ],
      "confidence": 0.9788236021995544
    },
    {
      "text": "Dekirmenjian, and Davis).",
      "bbox": [
        69,
        568,
        260,
        589
      ],
      "confidence": 0.9925681352615356
    },
    {
      "text": "Address for reprint requests: Behavioral Neurochemistry, Texas Research Institute",
      "bbox": [
        72,
        646,
        703,
        667
      ],
      "confidence": 0.9842988848686218
    },
    {
      "text": "of Mental Sciences, 1300 Moursund, Texas Medical Center, Houston, Texas 77030 (Or.",
      "bbox": [
        73,
        664,
        709,
        684
      ],
      "confidence": 0.9804720282554626
    },
    {
      "text": "Smith).",
      "bbox": [
        74,
        681,
        131,
        700
      ],
      "confidence": 0.9982547760009766
    }
  ],
  "full_text": "BLOOD LEVELS OF NEUROLEPTIC DRUGS IN\nNON-RESPONDING CHRONIC SCHIZOPHRENIC PATIENTS\nRobert C. Smith, M.D., Ph.D.\nH. Dekirmenjian, Ph.D.\nJohn Crayton, M.D.\nDavid Klass, M.D.\nJohn M. Davis, M.D.\nFrom the Texas Research Institute of Mental Sciences, Houston, Texas (Dr. Smith),\nManteno State Hospital, Manteno, I1linois (Drs. Smith, Crayton, and Klass), the\nIllinois State Psychiatric Institute, Chicago, Illinois (Dr. Dekirmenjian, Crayton,\nand Davis), and the Unviersity of Chicago, Department of Psychiatry (Drs. Crayton,\nDekirmenjian, and Davis).\nAddress for reprint requests: Behavioral Neurochemistry, Texas Research Institute\nof Mental Sciences, 1300 Moursund, Texas Medical Center, Houston, Texas 77030 (Or.\nSmith)."
}